Full Text View
Tabular View
Study Results
Related Studies
Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)
This study has been completed.
Study NCT00538915   Information provided by Biotest Pharmaceuticals Corporation

First Received on October 1, 2007.   Last Updated on February 23, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
More general conditions related to this trial
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Sponsors listed in this trial